Melatonin-Loaded Sacchachitin Hydrogel for Atopic Dermatitis Therapy

Study Background and Research Question

Atopic dermatitis (AD) is a chronic inflammatory skin disorder marked by pruritus, barrier dysfunction, and immune dysregulation. Affecting up to 20% of children and 3% of adults, AD presents a significant medical and societal burden due to its persistent nature and frequent comorbidities (Lin et al., 2026). Standard treatments—primarily topical corticosteroids and calcineurin inhibitors—can be effective but often come with side effects such as skin atrophy and systemic immunosuppression. The search for safe, steroid-sparing topical therapies that restore the skin barrier and modulate immune responses remains a pressing clinical need. Lin et al. addressed this gap by developing a biocompatible, non-steroidal hydrogel platform for topical AD therapy.

Key Innovation from the Reference Study

The central innovation of this study is the creation of a hydrogel composed of sacchachitin nanofibers (SCNFs) loaded with melatonin. SCNFs, derived from chitin, serve as a structural scaffold providing mechanical stability and facilitating topical application, while melatonin acts as the principal immunomodulatory agent. The resulting melatonin-loaded SCNF hydrogel (MSC) is designed to combine the biocompatibility and adhesive qualities of the scaffold with the anti-inflammatory and antioxidative properties of melatonin, offering a dual-action, non-steroidal platform for managing AD.

Methods and Experimental Design Insights

Lin et al. employed a comprehensive approach to evaluate the MSC hydrogel. Physicochemical characterization confirmed the stable incorporation of melatonin without compromising the hydrogel’s mechanical properties or adhesiveness. The stability of melatonin was assessed over 31 days, ensuring the therapeutic agent remains chemically intact during typical storage and use. For in vivo efficacy, a 2,4-dinitrochlorobenzene (DNCB)-induced AD model was established in NC/Nga mice—a standard model that recapitulates key features of human AD, including epidermal hyperplasia, immune cell infiltration, and Th2-type immune responses. The therapeutic potential of the MSC hydrogel was evaluated against multiple controls, including SCNF hydrogels without melatonin and untreated groups. Clinical severity scores, histological analysis, and quantification of immunological biomarkers (IgE, IgG1, IL-4) provided a robust readout of efficacy and mechanism.

Protocol Parameters

• Hydrogel preparation: Sacchachitin nanofibers were processed to form a hydrogel scaffold, followed by uniform incorporation of melatonin for final concentrations optimized for topical application.
• Stability testing: Melatonin integrity within the hydrogel matrix was monitored for a minimum of 31 days at relevant storage conditions.
• In vivo AD model: NC/Nga mice were sensitized and challenged with DNCB to induce atopic dermatitis, followed by topical treatment with MSC hydrogel for designated time intervals.
• Outcome measures: Disease severity scores, histopathology (epidermal thickness, mast cell infiltration), and serum immunoglobulin/ cytokine levels (IgE, IgG1, IL-4) were quantified to assess therapeutic impact.

Core Findings and Why They Matter

Among all tested formulations, the melatonin-loaded SCNF hydrogel (MSC) delivered superior therapeutic outcomes. Key findings from the reference study include:

• Significant reduction in AD severity: MSC-treated mice exhibited marked improvement in clinical scores, with notable decreases in erythema, edema, and lichenification compared to controls.
• Histological evidence of barrier restoration: Epidermal hyperplasia and mast cell infiltration were substantially reduced, indicating restoration of skin structure and suppression of allergic inflammation.
• Immunomodulation: MSC hydrogel application led to significant decreases in Th2-associated markers (serum IgE, IgG1, and IL-4), suggesting effective dampening of the pathogenic immune response.
• Stability and compatibility: Melatonin remained chemically stable for at least 31 days within the hydrogel, and the SCNF matrix retained its mechanical and adhesive properties throughout the study.

These results underscore the potential of the MSC hydrogel as a steroid-sparing, biocompatible topical therapy capable of addressing both barrier dysfunction and immune dysregulation in AD.

Comparison with Existing Internal Articles

The workflow and mechanistic rigor of Lin et al. align with best practices highlighted in several internal resources. For instance, the importance of protein integrity in immunological assays—such as those measuring cytokines and immunoglobulins—is emphasized in internal guidance on EDTA-free protease inhibitor cocktails. Use of a protein extraction protease inhibitor is recommended when processing skin or immune tissues for biomarker analysis, ensuring that proteolytic degradation does not compromise data quality.

Moreover, the translational outlook of Lin et al.—advancing from basic barrier repair to integrated immune modulation—echoes the forward-looking perspective described in articles on safeguarding protein complexes in mammalian research. Such attention to workflow optimization, from tissue collection to downstream kinase or immunoassays, is central to reproducible biomedical research.

Limitations and Transferability

While the findings are compelling, several limitations should be considered. First, the study was conducted in a murine AD model; although NC/Nga mice recapitulate many aspects of human disease, direct clinical translation requires further validation in human tissues or clinical trials. Additionally, the long-term safety and efficacy of repeated melatonin hydrogel application remain to be explored, especially in the context of chronic human use. The precise mechanism by which melatonin modulates Th2 responses in situ also warrants further mechanistic dissection. Finally, while the SCNF scaffold is biocompatible, scaling up manufacturing and ensuring batch-to-batch reproducibility are nontrivial translational hurdles.

Research Support Resources

For researchers seeking to replicate or extend these workflows—particularly those involving immunological protein quantification, Western blot, or co-immunoprecipitation from skin or immune tissues—the use of a robust protease inhibition strategy is essential. The Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) (SKU K1010) from APExBIO offers broad-spectrum inhibition without interfering with divalent-cation-dependent assays, supporting reliable sample preparation in studies examining protease-sensitive targets. This is particularly relevant for workflows sensitive to phosphorylation status or native protein complexes, as highlighted in recent internal resources. By integrating such research tools, investigators can ensure data integrity throughout translational skin disease research.